For most clinical programs, recruitment is the single largest source of delay. It is often more operationally complex than the trial itself, and when it underperforms, the consequences extend well beyond the enrollment timeline. Protocols stall, costs compound, and treatments reach patients later than they should. The challenge is not simply finding patients. It is identifying the right patients, qualifying them efficiently, and maintaining their engagement across an increasingly complex study lifecycle.
CRISPR (clustered regularly interspaced short palindromic repeats) and CRISPR-associated (Cas) proteins were first characterized as part of bacterial immune defense and later adapted into programmable genome editing tools that enable site-specific DNA modification. This shift from microbial biology to clinical development has made CRISPR a central technology in precision medicine, including the first approved therapies for inherited blood disorders (NSF).
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a progressive liver disease driven by fat accumulation that triggers chronic inflammation and fibrosis. It represents the more severe end of the metabolic dysfunction-associated steatotic liver disease (MASLD) spectrum, which ranges from simple steatosis to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Without intervention, MASH can lead to irreversible liver damage.
Pharmacogenomics, also known as pharmacogenetics, is a field of research dedicated to investigating how an individual's genetic makeup influences their response to medications. Because pharmacogenomic testing analyzes germline DNA, the results remain valid for life, making PGx a foundational resource for clinical decision-making across a patient's entire care journey.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Dimitar Tonev, an expert in liver disease and hepatology, sheds light on the latest developments in liver disease – particularly metabolic dysfunction-associated steatohepatitis (MASH) – including significant changes and predictions for the future.
Keeping participants engaged in clinical research can be difficult. Here, we let the statistics tell the story:
Genetic data is at the heart of precision medicine. Understanding the influence of genetics on health has helped us to recognise risk factors for disease, predict how patients might respond to treatments, and develop targeted treatments. But how does this knowledge connect to phenotypic data – the expression of the interaction between genes and the environment?
DPharm 2023 has come to a close, and as we reflect on the sessions and insights shared, two themes clearly stood out this year: The participant experience and incentives for participants. In this blog, we’ll dive deeper into these central areas of discussion.
As COVID-19 continues to affect us all, it has become evident that our fight against the virus is not just about developing vaccines and therapeutics. Equally crucial is our ability to track the virus’s mutations and adaptations. Enter genomic sequencing – a technology that has taken centre stage in our ongoing battle against the pandemic. Here, we explore how genomic sequencing has been instrumental in tracking SARS-CoV-2 variants and its implications for future pandemics.
In this blog, we're exploring whether ALS can be caught early, including the tests that may be used in order to diagnose ALS, and if there are any measures that can be put in place to stop it early.